Skip to content

Tracking anti-microbial resistance across care settings in Liverpool (TRACS-Liverpool) Part 2

Tracking anti-microbial resistance across care settings in Liverpool (TRACS-Liverpool) Part 2: an observational cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN17060051
Enrollment
651
Registered
2022-09-28
Start date
2023-02-01
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transmission of antimicrobial resistance within and between care settings in Liverpool including NHS wards, intermediate care and long term residential care Infections and Infestations

Interventions

Following consent and enrolment participants will be asked to provide up to five stool samples or rectal swabs over a 2-week period of site-specific sampling. Each site will be revisited approximately

Sponsors

Liverpool School of Tropical Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All current adult (aged =18 years) residents of the study sampling location during the sampling period

Exclusion criteria

Exclusion criteria: Residents being managed with palliative intent in whom active treatment has been withdrawn

Design outcomes

Primary

MeasureTime frame
The presence of ESBL-E/CPE will be defined by selective culture of stool or rectal swab. Samples will be collected from all residents of the sampling area (hospital ward or care home) at 5 time-points over the two week sampling period at that location. Sample areas will be visited 4 times over the course of the study at 12 week intervals. If participants are still present the sampling schedule will be repeated. Hazard ratio of ESBL-E/CPE acquisition: The ESBL-E/CPE presence/absence data will be used to fit multistate Markov models. In these models participants can be either colonised or uncolonised with a transition rate between each state. The transition rate is governed by a linear combination of covariates, which can be included in such a way that the effect of the covariate can be interpreted as a hazard ratio. Hence by including care home (versus hospitalisation) as a covariate in the models this will generate a hazard ratio of ESBL acquisition for care home residency versus hospitalisation.

Secondary

MeasureTime frame
1. Parameter values for effect of covariates from multistate models including hazard of ESBL-E/CPE acquisition measured by including other covariates in the Markov multistate models, this will generate estimates of the effect of the included covariates, analogously to the hazard ratio of ESBL acquisition described above. The values of these parameters (i.e. estimated quantities from the model) will allow an understanding of the effect of the included covariates. 2. Description of putative transmission events (bacteria and mobile genetic elements and routes within and between hospitals and care facilities. We will sequence the genomes of cultures bacteria using short read whole genome sequencing and map them to a reference genome. We can then compare genomes using the number of single nucleotide polymorphisms (SNPs) between them. Very closely related bacteria (i.e., < 10 SNPs) are putative transmission events. We will describe these transmission events in terms of which compartments (patient, environment, staff) are most linked to allow an understanding of likely transmission routes ). To describe mobile genetic elements we will use long read sequencing with a similar analysis. 3. Longitudinal description of within-host ESBL-E/CPE diversity. We will describe within-participant diversity by limited diversity metagenomics following selective culture of samples for ESBL-E/CPE. This technique allows sequencing of all ESBL-E/CPE organisms in a sample with subsequent computation reconstruction of the different bacteria present. We will present a descriptive analysis of the diversity of ESBL-E/CPE strains within participants and the effect on the diversity of exposure to antimicrobials, hospitalisation, and residence in care homes.

Countries

England, United Kingdom

Contacts

Public ContactMaria Moore
maria.moore@lstmed.ac.uk+44 (0)151 705 2566

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026